pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·1h ago·1 min read
save

Fragile X at a turning point: Breaking through the clinical bottleneck

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.

Aug 27, 2026·read at BioSpace ↗

News Drug Development Fragile X at a turning point: Breaking through the clinical bottleneck August 27, 2026 | 1 min read | Jennifer C. Smith-Parker, BioSpace Insights Twitter LinkedIn Facebook Email Print In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.

> Listen on Spotify> Listen on Apple Podcasts> Listen on Amazon Music> Watch on YouTubeIn this episode of Denatured, you’ll listen to Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From the challenge of credible endpoints and persistent placebo effects to the promise of neuroplasticity modulation, we examine the steps needed to move the field toward its first approved therapy.Host⁠Jennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsHilary Rosselot, Executive Director, National Fragile X FoundationJordi Fàbrega, Co-Founder & CEO, CONNECTA TherapeuticsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Twitter LinkedIn Facebook Email Print Podcasts BioSpace Insights Denatured Clinical research Europe Rare diseases Regulatory Patient recruitment FDA Patient advocacy Fragile X Jennifer C. Smith-Parker Jennifer C. Smith-Parker is Director of Insights at BioSpace.

She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

BioSpace Insights The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.

source

Reporting by BioSpace.

read at BioSpace ↗
305 words · retrieved 15m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoThe great disconnect: 4 ways companies, job candidates misalignBioSpace
  • 2h agoNearly 1/4 dealing with long-term unemployment call it quits on biopharma job searchesBioSpace
  • 3h agoCAR Ts will only treat autoimmune diseases if we can scale deliveryBioSpace
  • 5h agoMyriad catalysts on deck for obesity’s brightest stars as market continues to accelerateBioSpace
  • 15h agoVitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concernsBioSpace